Saturday, 31 October 2026European Markets

MAGNORA And NEOEN Have A High Dividend Yield And Return On Equity In The Utilities Sector.

Loading stream...

(vianews) - magnora (mgn.ol) is among this list of stock assets with the highest dividend rate and return on equity on the utilities sector.

financial asset price forward dividend yield return on equity
magnora (mgn.ol) kr26.15 27.96% 3.91%
neoen (neoen.pa) €26.24 0.39% 3.27%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. magnora (mgn.ol)

27.96% forward dividend yield and 3.91% return on equity

magnora asa operates as a renewable energy development company in norway, sweden, and the united states. the company primarily focuses on developing wind, solar photovoltaic (pv), and battery storage projects. it also hold license agreements with the dana western isles and shell penguins. it serves renewable energy operators, investment and oil companies, and global marine contractors. the company was formerly known as sevan marine asa and changed its name to magnora asa in october 2018. magnora asa was incorporated in 2001 and is based in oslo, norway.

earnings per share

as for profitability, magnora has a trailing twelve months eps of kr0.48.

pe ratio

magnora has a trailing twelve months price to earnings ratio of 54.48. meaning, the purchaser of the share is investing kr54.48 for every norwegian krone of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 3.91%.

moving average

magnora's value is way under its 50-day moving average of kr30.49 and way under its 200-day moving average of kr30.59.

sales growth

magnora's sales growth is 4902.6% for the current quarter and 145.6% for the next.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, magnora's stock is considered to be oversold (<=20).

growth estimates quarters

the company's growth estimates for the present quarter and the next is 1264% and 204.2%, respectively.

more news about magnora.

2. neoen (neoen.pa)

0.39% forward dividend yield and 3.27% return on equity

neoen s.a., an independent renewable energy production company, engages in the development and operation of renewable energy power plants. the company operates through solar power, wind power, storage, farm-down, development and investments, and eliminations segments. it operates in argentina, australia, canada, ecuador, the united states, finland, france, ireland, italy, jamaica, mexico, mozambique, portugal, el salvador, sweden, and zambia. neoen s.a. was incorporated in 2008 and is headquartered in paris, france.

earnings per share

as for profitability, neoen has a trailing twelve months eps of €0.94.

pe ratio

neoen has a trailing twelve months price to earnings ratio of 27.91. meaning, the purchaser of the share is investing €27.91 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 3.27%.

yearly top and bottom value

neoen's stock is valued at €26.24 at 22:30 est, way under its 52-week high of €38.54 and way above its 52-week low of €21.80.

more news about neoen.

In this story · Knowledge Files

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com